Expert Hans Hammers, MD, reviews a case of a 59-year-old African American woman who underwent nephrectomy for left renal mass revealing clear cell RCC, who later developed metastatic disease managed initially with pembrolizumab and lenvatinib.
EP. 1: Initial Clinical Impression Description
Dr. Hammers discusses initial impressions of the case presentation, comparing it to typical advanced RCC, and reviewing risk factors.
Watch
EP. 2: Perspective on Initial Therapy Selection
Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.
EP. 3: CLEAR Study Efficacy Data Description
Dr. Hammers summarizes key efficacy findings from the CLEAR study of pembrolizumab + lenvatinib vs sunitinib.
EP. 4: Immunotherapy-Based Regimen Efficacy/Safety Updates
Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.
EP. 5: Factors in Treatment Selection
Dr. Hammers explains factors involved in decision-making between immunotherapy-based treatment options.
EP. 6: Managing Grade ≥3 Adverse Events
Dr. Hammers shares his experience with high-grade AEs in IO-TKI treated patients and how toxicities are mitigated/managed.
EP. 7: Toxicity Management Approach
Dr. Hammers outlines his thought process around TKI/ICI dose modifications vs discontinuations with toxicity and discusses toxicity management recommendations.
EP. 8: Quality of Life Considerations
Provide perspective on quality-of-life observations with different IO-TKI regimens and supporting evidence.
EP. 9: Future Management of Advanced RCC
Dr. Hammers discusses future management for advanced RCC, unmet needs, and emerging data being monitored.